Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag
TH Open · 24.07.2026 · 10 (CP)
DOI: 10.1055/a-2886-7426 ↗Kurz gefasst
Fachartikel in der Zeitschrift TH Open, erschienen am 24.07.2026. Verfasst von Quentin A Hill und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of HematologyLeeds Teaching Hospitals NHS TrustLeedsEnglandUnited Kingdom of Great Britain and Northern Ireland. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Clinical trials indicate that avatrombopag, a thrombopoietin-receptor agonist (TPO-RA), is safe and effective for treating patients with primary immune thrombocytopenia (ITP), but real-world evidence on its broader clinical effectiveness is limited.
Methods
This European multi-center retrospective chart review included adults with primary ITP treated with avatrombopag in routine clinical practice, who had medical records available for ≥ 12 weeks before and after avatrombopag initiation.
Results
Data from 76 patients with ITP (51 TPO-RA naïve, 25 prior TPO-RA exposed) showed a median time of 4.2 years (interquartile range: 0.7–10.3) from ITP diagnosis to avatrombopag initiation (index date) and a median follow-up of 15.9 months (interquartile range: 7.8–22.8). By week 12, 96 and 93% of the cohort achieved platelet counts (PC) of ≥30 × 109/L and ≥50 × 109/L, respectively; 72% had a complete response (≥100 × 109/L) by week 12, 80% by week 26, and 87% by week 52 postindex. PC reached ≥30 × 109/L, ≥50 × 109/L, and ≥100 × 109/L in a median of 8 (95% confidence interval: 7–12), 10 (8–14), and 19 (12–23) days from the index date, respectively. At 1 year, 75% (n total = 34) and 47% (n total = 21) maintained PC of ≥50 × 109/L and ≥100 × 109/L, respectively. Avatrombopag was permanently discontinued by 19 patients (25%), including 7 (37%) due to being candidates for sustained remission off-treatment. Thromboembolic rates were 4.9 (95% confidence interval: 1.3–12.5) per 100 patient-years during follow-up. The incidence rate (95% confidence interval) of ITP-related outpatient visits and inpatient admissions was 8.9 (8.2–9.5) and 0.1 (0.1–0.2) per person-year.
Conclusion
This study supports clinical trials’ findings and other postmarketing evidence demonstrating the effectiveness of avatrombopag.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of HematologyLeeds Teaching Hospitals NHS TrustLeedsEnglandUnited Kingdom of Great Britain and Northern Ireland.
- Department of Medical Sciences, University of TriesteTriesteFriuli-Venezia GiuliaItaly.
- Hematology Unit (SC/UCO)Azienda Sanitaria Universitaria Giuliano IsontinaTriesteFriuli-Venezia GiuliaItaly.
- Department of HematologyHospital Universitario Reina SofíaCórdobaSpain.
- Department of Internal Medicine, Hematology and OncologyUniversity Hospital BrnoBrnoSouth Moravian RegionCzech Republic.
- Department of HematologyUZ LeuvenLeuvenFlandersBelgium.
ORCID-Profile: Fatemeh Saberi Hosnijeh
Zitieren
APA
Hill, Q. A., Zaja, F., Sánchez de Mora, M. D. C. F., Cervinek, L., Janssens, A., Hosnijeh, F. S., Le Treust, L., Glen, F., Putnik, M., Rich, C., & Miesbach, W. (2026). Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag. TH Open, 10(CP). https://doi.org/10.1055/a-2886-7426
Vancouver
Hill QA, Zaja F, Sánchez de Mora MDCF, Cervinek L, Janssens A, Hosnijeh FS, et al. Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag. TH Open. 2026;10(CP). doi:10.1055/a-2886-7426
BibTeX
@article{Hill2026,
author = {Hill, Quentin A and Zaja, Francesco and Sánchez de Mora, María Del Carmen Fernandez and Cervinek, Libor and Janssens, Ann and Hosnijeh, Fatemeh Saberi and Le Treust, Luca and Glen, Fiona and Putnik, Milica and Rich, Carly and Miesbach, Wolfgang},
title = {Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag},
journal = {TH Open},
year = {2026},
volume = {10},
number = {CP},
doi = {10.1055/a-2886-7426}
}
EUVIMED